INTRODUCTION
Chronic HCV infection is an important cause of liver fibrosis leading to cirrhosis, end-stage liver disease and the development of hepatocellular carcinoma.
1 Treatment with pegylated interferon (peg-IFN)-α and ribavirin (RBV), has achieved sustained viral response (SVR) in approximately 45% of patients infected with genotype 1, 50%-60% of genotype 4 patients, and up to 80% of patients infected with genotypes 2 or 3. [2] [3] [4] Emerging data suggest that SVR may be associated with improved long-term clinical outcomes, including increased survival.
5
Most patients tolerate peg-IFN/RBV poorly and many are not good candidates for this treatment combination due to advanced liver disease or concurrent medical conditions. Furthermore, those who failed peg-IFN/RBV have poor SVR rates after retreatment with peg-IFN/RBV.
6,7
These problems have prompted the development of direct-acting antiviral agents, which, in combination with peg-IFN/RBV have led to increased cure rates and shorter treatment durations. while preserving high SVR rates. The primary disadvantages of telaprevir and boceprevir are development of viral resistance in patients who do not achieve SVR, three times daily administration and additional side effects, such as rash and anaemia. 79
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Pharmacokinetics
From the single-dose cohorts, serial plasma samples were collected after dosing, followed by daily sampling for 5 days post-dosing. Urine pharmacokinetic samples were collected for 5 days post-dosing. Intensive pharmacokinetic sampling was performed over 24 h after the first and third IDX320 dosing days during the multiple-dose sections, followed by daily sampling for 5 days after the last dose. Non-compartmental analyses were performed to generate principal plasma pharmacokinetic parameters including total exposure (area under the curve [AUC]), maximum concentration (Cmax), time to reach Cmax (Tmax), trough concentrations (Ctrough;
C24 h for once daily and C12 h for twice daily) and half-life. Plasma concentrations of IDX320
were determined using a validated liquid chromatographic-tandem mass spectrometric method, with a limit of quantification of 2.0 ng/mL.
Viral assessments
HCV genotype and subtype were determined at screening, using two methods. Genotyping of patients was performed as described by Murphy et al. Multiple samples for determination of plasma HCV RNA levels were obtained during the IDX320 treatment period and for 5 days post-dosing. In the multiple-dose studies, a sample was also obtained 7 days post-dosing and at the final follow-up visit on day 28. HCV RNA was quantitated by a validated real-time PCR assay (COBAS® TaqMan®; Roche, Pleasanton, CA, USA), with a quantification range of 43-69×106 IU/mL and a lower limit of detection of 15 IU/mL. Genotyping of IL28B single nucleotide polymorphism rs12979860 was determined by direct sequencing. 20 Patients were not randomized or stratified according IL28B genotype.
Viral resistance analysis
In the single-dose study, plasma samples were collected prior to treatment and during 5 days after dosing (Part B). In the multiple ascending-dose study (Parts C and D), plasma samples were collected from all patients prior to treatment, and 1 and 4 days after the final dose for population sequencing (DDL Diagnostic Laboratory, Voorburg, the Netherlands). All samples with a viral load ≥1,000 IU/mL were sequenced. RNA was isolated using the QIAGEN MinElute Virus Spin Kit (Qiagen GmbH, Hilden, Germany) The NS3 through NS4A region of the HCV genome was converted into complementary DNA by the Roche Transcriptor kit and amplified by nested PCR using the Expand High Fidelity kit (Roche Diagnostic GmbH, Mannheim, Germany).
Purified PCR products were sequenced from both directions using the BigDye® Terminator v1.1
Cycle Sequencing Kit (Applied Biosystems, Inc., Foster City, CA, USA). Sequences were then manually edited and assembled using SeqScape software (Applied Biosystems). When two or more fluorescence signals were obtained at a single nucleotide base position, a mixed base was called if the lowest signal exceeded 25% of the highest signal, as recommended by the software manufacturer.
prior to enrolling HCV-infected patients. The first part (Part A) was a randomized double-blind placebo-controlled sequential dose-escalation in 48 healthy male subjects. Eight subjects per dose level were randomized to receive, in a 6:2 ratio, either IDX320 or matching placebo. Six IDX320 dose levels were explored: a single dose of 50, 100, 200 or 400 mg in the fed state, 400 mg in the fasted state and 400 mg once-daily in the fed state for 3 days. The second part Placebo and IDX320 were administered in the fed state to all patients. After 3 days of IDX320 monotherapy, patients were offered extended therapy with peg-IFN-α2a (180 μg/week) and weight-based RBV (1,000 or 1,200 mg/day) for up to 48 weeks. Patients were confined for 7 days after dosing and returned for additional follow-up 3-4 weeks after the dosing period.
The study was conducted from January 2010 to August 2010. This study was conducted in accordance with Good Clinical Practice and with the World Medical Association Declaration of Helsinki after approval by the ethics committee at each site. All subjects provided written informed consent before participating in any study-related activity.
IDX320 dosing was conducted as an inpatient study; peg-IFN/RBV was administered on an outpatient basis. Study medication was supplied by Idenix Pharmaceuticals, Inc (Cambridge, MA, USA). IDX320 and matched-placebo were orally administered as 50 mg tablets. Treatment was prepared by designated site pharmacists, who were not involved in the study procedures, assessments or data recording and did not reveal the randomization during the study according to the CONSORT guidelines. 18 Treatment was dispensed in a blinded fashion by study staff for administration to the subjects.
Inclusion criteria of healthy volunteers and hepatitis C patients
To determine eligibility, healthy male volunteers underwent a medical evaluation that included a physical examination, medical history, electrocardiogram, laboratory tests, urinalysis and virus serology testing for HCV, HBV and HIV.
Chronic hepatitis C patients were males and females, between 18 and 65 years, with a body mass index (BMI) 18-35 kg/m2 , HCV RNA≥5 log 10 IU/mL, genotype 1 infection, alanine aminotransferase (ALT) ≤5x the upper limit of normal and no other clinically significant laboratory abnormalities. In the single-dose study, inclusion of both IFN treatment-naive and treatment-experienced patients was allowed. Only treatment-naive patients were included in the multiple-dose studies. Key exclusion criteria were decompensated liver disease, Child Pugh B/C liver cirrhosis, hepatocellular carcinoma, and coinfection with HBV or HIV. 81
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One patient randomized to the 50 mg IDX320 once-daily cohort was incorrectly dosed with 400 mg IDX320 once-daily for 3 days and has been included in the 400 mg once-daily group in the analyses. 27 (10) 37 (21) 29 (16) 42 (16) 38 (17) 43 (5) 53 ( Multiple, n 0 0
21 (2) 25 (4) 26 (2) 25 (3) 22 (2) 24 (1) 25 (5) a Ten single-dose subjects plus two multiple-dose subjects. BMI, body mass index.
Pharmacokinetics of IDX320 in healthy volunteers and chronic hepatitis C patients
Following oral administration of a single ascending dose in healthy subjects under fed conditions, peak and total plasma exposures of IDX320 were less than dose-proportional. An eightfold increase in dose, from 50 to 400 mg, led to an approximate threefold to fourfold increase in mean Cmax and AUC∞. By contrast, Ctrough at 24 h appeared dose-proportional with a 10-fold increase in the studied dose range. Mean Cmax was reached at a median Tmax of 3 h regardless of dose. Mean terminal half-life was 24-26 h for doses ≥100 mg.
One treatment-naive and one treatment-experienced patient received a single 200 mg dose and their plasma exposures of IDX320 did not appear to be substantively higher compared to healthy subjects considering the variability associated with a small sample size. IDX320
exposure was 2-3-fold higher with food compared to fasting state. Median Tmax remained consistent at 3 h.
Similar to the observations in healthy subjects, plasma exposure of IDX320 in HCV-infected patients was less than dose-proportional (Additional file 1). Following repeated once-daily and twice-daily dosing for 3 days, IDX320 did not appear to appreciably accumulate in terms of C max and AUC considering the associated interindividual variability. The IDX320 mean terminal halflife ranged from 25.2 to 28.9 h in the once-daily dosing groups and was 52.6 h in the twice-daily dosing group. There was a steady increase in C trough over time. For the same total daily dose, while maintaining comparable peak exposure, trough concentrations were approximately 2 to 3-fold higher with the 200 mg twice-daily dose than with the 400 mg once-daily dose. Overall,
Safety assessments
All subjects were monitored for safety and tolerability at regular intervals from the start of IDX320 dosing through completion of the follow-up visits. Safety assessments included clinical history, routine laboratory evaluations, physical examination, 12-lead electrocardiograms, vital signs and the recording of all adverse events. 
RESULTS

Baseline characteristics of healthy volunteers and hepatitis C patients
A total of 48 healthy subjects and 40 HCV-infected patients were enrolled ( Figure 1 ). Baseline characteristics of healthy volunteers and HCV-infected patients are summarized in Tables 1 and   2 , respectively. Demographic characteristics and BMI at baseline were generally comparable across the groups in both healthy subjects and HCV-infected patients, with the exception of age in the healthy volunteers. HCV-infected groups were comparable with regards to HCV RNA Antiviral activity of IDX320 in chronic hepatitis C patients -CHAPTER 4 curves are displayed in Figure 2B . A total of 26 (68%) patients initiated peg-IFN/RBV after 3 days IDX320 monotherapy. Treatment response at day 28 in those patients who received peg-IFN/ RBV during the follow-up period are displayed in Table 4 . One patient randomized to the 50 mg QD cohort was incorrectly dosed and received 400 mg once for 3 days. ‡ Undetectable HCV RNA levels (<15 IU/mL) of patients who received pegylated interferon-alfa and ribavirin during the follow-up period are shown. QD, once daily; BID, two times daily.
peak and total plasma exposures of IDX320 in HCV-infected patients and healthy subjects were comparable (Table 3) . C troughs were approximately twofold higher in HCV-infected patients at doses ≥200 mg once-daily compared to healthy subjects. C trough on day 3 ranged from 65 to 274 ng/mL for the IDX320 once-daily dosing regimens, while EC 50 /EC 90 values were 2.7/4.2 ng/mL in the genotype 1a replicon and 0.4/1.2 ng/mL in the genotype 1b replicon. Urine excretion of IDX320 was negligible (<0.01% of administered doses). (1) 24 (4) 25 (2) 27 (3) 26 (5) 28 (5) 25 (3) Mean HCV RNA, 
Antiviral activity
Antiviral activity of IDX320 was first observed in two genotype 1a HCV-infected patients, who received a single dose of 200 mg. Maximal HCV RNA reductions were 1.9 log 10 IU/mL at 12 h in the treatment-naive patient and 2.8 log 10 IU/mL at 36 h in the treatment-experienced patient after a single dose. Mean changes in HCV RNA for the 38 treatment-naive patients who received IDX320 monotherapy for 3 days are displayed in Figure 2A and Table 4 . IL28B genotype status appeared to have no effect on antiviral activity through day 3. None of the patients experienced virological breakthrough (defined as a 1 log 10 increase of HCV RNA above nadir) during IDX320 treatment. No patient achieved undetectable levels of HCV RNA by day 3. Individual HCV RNA 85
Safety and tolerability
All enrolled healthy subjects and HCV-infected patients completed the study. There were no serious adverse events. A summary of the reported clinical adverse events in chronic hepatitis C-infected patients is listed in Table 5 . Adverse events during the IDX320 treatment period were rare, mild to moderate in intensity and without any discernable patterns between the IDX320 treatment groups and placebo groups. With the exception of one patient (200 mg oncedaily group) with a single grade 3 serum calcium decrease among otherwise normal calcium values, and another patient (200 mg twice-daily group) who had an asymptomatic increase in lipase from grade 2 at screening to grade 3 on day 2 (pancreatic amylase remained normal), laboratory abnormalities during the IDX320 treatment period were all grade 2 or below, the majority being grade 1. With the exception of bilirubin, there were no patterns in graded laboratory abnormalities noted between the IDX320 and placebo groups. Although comparable to placebo in the IDX320 once-daily treatment groups, there were more grade 1/2 total serum bilirubin elevations in the 200 mg twice-dailiy treatment group (Table 5 ). The elevations were primarily of direct bilirubin. Patients with bilirubin increases were asymptomatic and did not have associated increases of ALT, aspartate aminotransferase (AST) or alkaline phosphatase.
Serum bilirubin returned to baseline levels within 4 days of the last dose of IDX320. Adverse events and laboratory abnormalities after the IDX320 treatment period were consistent with peg-IFN/RBV dosing, which began immediately after the IDX320 treatment period in the majority of patients. Table 5 . Summary of all adverse events and Grade 1 or 2 total bilirubin elevations during the IDX320 treatment period in chronic hepatitis C patients. 
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IDX320 demonstrated potent dose-related antiviral activity in genotype 1 HCV-infected patients. There was a pharmacokinetic/pharmacodynamic relationship between the day 3 viral response and the Ctrough of IDX320 following the third dose, such that higher Ctroughs were associated with better antiviral responses (Additional file 2). Antiviral activity beyond the IDX320 or placebo monotherapy period was difficult to assess since peg-IFN/RBV was not initiated in all patients (n=12). Nevertheless, 13 (62%) patients who received IDX320 for 3 days followed by peg-IFN/RBV achieved undetectable levels of HCV RNA by day 28. This compared to no patients (n=5) who received placebo prior to peg-IFN/RBV therapy.
A secondary objective was to investigate the pharmacokinetic profile including the effect of food intake. IDX320 was well absorbed with dose-related drug exposure and no appreciable accumulation. IDX320 plasma concentrations in healthy subjects were above the targeted pharmacologically relevant drug exposure and were 40-to 150-fold above the genotype 1a 
Mutational analysis
Previous in vitro work with IDX320 selection experiments and evaluation of site-directed mutants identified the D168 locus as the primary site of resistance to IDX320, with several other sites (Q80, R155 and A156) conferring mild to moderate resistance to IDX320 when mutated. 15 Population sequences from the entire NS3/NS4A region were analysed before and after treatment. Random, low frequency substitutions were observed throughout the NS3/ NS4A region, but several post-treatment changes were observed at loci known to confer in vitro resistance to IDX320, specifically loci Q80, A156 and D168.
Neither of the two patients enrolled in the single-dose part of this study showed a change at any of the resistance loci, nor did any of the patients enrolled in the three-day dosing portion of the study who received IDX320 show any resistance variants at baseline. Two genotype 1a patients had a baseline R80 polymorphism. Both patients were assigned to receive placebo and were therefore not included in this analysis.
Overall, 6 of 30 genotype 1b patients receiving IDX320 for 3 days developed mutations at day 3 at three loci that are associated with in vitro resistance to IDX320 (Table 6 ). Two patients had Q80R, one patient had A156T, two patients had D168V and one patient had a mixed population of G/D at position 168. No changes at amino acid R155 were observed. D168G was not observed in the in vitro selection experiments; however, because the D168 locus was observed to mutate in vitro in response to IDX320 treatment, the D168G/D patient was included in the resistance summary.
All 6 patients whose virus developed mutations that conferred resistance in vitro (plus the D168G/D) showed substantial declines in viral load at day 3 relative to baseline (Table 6 ). In 3 patients, whose viral loads increased after the completion of IDX320 dosing, the observed day EC50 and approximately 300-to 1,000-fold above the genotype 1b EC50 after repeat daily dosing of IDX320 400 mg for 3 days. In HCV-infected patients in Parts C and D, IDX320 peak and total exposures were similar to exposures in healthy subjects. Ctrough remained consistently higher in HCV-infected patients compared to healthy subjects. A steady increase in Ctrough well above the replicon EC50 was observed during the 3-day IDX320 dosing period for all dose levels. The mean Ctrough of IDX320 achieved in the 400 mg once-daily regimen on day 3 was 274 ng/mL, representing 685× the EC50 value and 228× the EC90 value determined in a genotype 1b replicon assay. Previously it was shown that coadminsitration of ritonavir enhanced the Ctrough of the NS3 protease inhibitor narlaprevir, allowing once-daily dosing.
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The high Ctroughs and the long elimination half-life of IDX320 observed in the 400 mg oncedaily dosing groups indicate that boosting with ritonavir would not be needed to allow once daily dosing with robust antiviral effect.
Single-day dosing of IDX320 did not result in the emergence of any mutations that have been correlated with resistance. In the 3-day dosing portion of the study, 6 of 30 patients infected with genotype 1b virus had NS3 mutations at three amino acids shown to be associated with resistance to IDX320 in vitro. The three loci that changed following IDX320 treatment in the clinic have been shown to confer mild (5.7-fold change in EC50 for Q80R), moderate (27-fold change in EC50 for A156T) or high (4,600-fold change in EC50 for D168V) resistance to IDX320 when examined in mutant genotype 1b replicons. 15 These variants were also observed with other macrocyclic NS3 inhibitors. 26 Viral load declines post-treatment in patients with NS3
mutations was not significantly different from the mean HCV RNA declines of their respective cohorts (Table 6 ).
A number of study limitations should be considered. The small numbers of subjects and patients per cohort could have biased the pharmacokinetic and antiviral treatment effect estimates. In addition, patients were almost all male, Caucasian and infected with HCV genotype 1b. The observed viral resistance rate may have been different if the study had included more genotype 1a patients, who have a lower genetic barrier for resistance. Clinical studies including a more heterogeneous study population with IFN-experienced patients, African-Americans, females and patients with liver fibrosis and/or cirrhosis would be warranted.
In conclusion, single and multiple doses for 3 days of IDX320 in healthy volunteers and HCVinfected patients were safe and well tolerated. Oral once-daily administration of IDX320 for 3 days resulted in a rapid HCV RNA decline in all patients. Although the results of this study demonstrated the clinical potential of IDX320, further development of IDX320 was stopped when three serious adverse events of increased liver enzymes occurred during a drug-drug interaction study of IDX320 and IDX184 (nucleotide HCV polymerase inhibitor) in 20 healthy volunteers.
